Ozempic Face: What Causes It and How to Prevent It

Dermatologists started noticing it in 2022: patients on GLP-1 medications were coming in looking noticeably older in the face, even as the rest of their health picture improved dramatically. The term "Ozempic face" entered the clinical lexicon and then the mainstream media — often framed as a hidden cost of the drugs. The reality is more nuanced: it's not a side effect of the medication itself. It's a consequence of rapid fat loss, and it's largely preventable if you understand the biology.

What is Ozempic face?

The term was coined by dermatologists — notably Dr. Paul Jarrod Frank, who described it publicly in 2022 — to describe the cluster of facial changes seen in patients experiencing rapid weight loss on semaglutide. The key features:

• Gaunt or hollowed-out appearance in the cheeks and temples
• Deepened nasolabial folds (the lines from nose to mouth corners)
• More prominent jowling as facial fat that was providing structural support disappears
• Loss of the "plumpness" that characterises a youthful face
• Skin that appears looser or less taut than expected

The critical distinction: this is not a pharmacological side effect of semaglutide or tirzepatide. The drug doesn't directly thin the face. Rapid fat loss does — and it has done so with every aggressive weight loss method throughout history, from crash diets to bariatric surgery. GLP-1 medications have simply made rapid, substantial weight loss accessible to a much larger population, making the phenomenon more visible.

It's more common in people over 40 and those losing weight quickly. Younger skin has more elasticity and adapts better to the structural changes. At any age, rate of loss is the primary modifiable risk factor.

The biology: why fast weight loss ages the face

The face contains several distinct fat compartments that contribute to its three-dimensional structure: the buccal fat pad (the fullness in the lower cheek), malar fat (over the cheekbones), orbital fat (around the eyes), and subcutaneous fat distributed throughout. These compartments are what give faces their rounded, youthful contour.

As the body loses fat, it draws from these compartments — not evenly across the body, but according to individual genetic patterns. Many people are genetically predisposed to lose facial fat early in weight loss, before more metabolically active abdominal fat has been fully mobilised. For these individuals, the face thins noticeably even at moderate total weight loss.

The second component is skin adaptation. Skin is elastic — but elasticity is finite and declines with age. When facial fat depletes faster than the overlying skin can contract and redrape, the result is excess skin relative to the underlying structure. This manifests as jowling, deepened lines, and a generally deflated appearance.

Protein insufficiency accelerates this further. Collagen — the structural protein that gives skin its tensile strength — requires adequate dietary protein to synthesise. When appetite suppression drives protein intake too low, collagen synthesis slows and existing collagen degrades faster. The skin loses structural integrity at the same time it's losing structural fat support. The combined effect is ageing that happens in months rather than years.

Who is most at risk?

Not everyone on GLP-1 medications develops noticeable Ozempic face. The factors that increase risk:

• Age over 40. Skin elasticity declines from the mid-30s onwards. At 50 or 60, the same rate of fat loss that leaves a 30-year-old largely unaffected can produce significant facial changes.
• Losing more than 0.75–1% of bodyweight per week. Rapid loss is the primary driver. This is the variable most directly under your control.
• Low protein intake. Collagen synthesis requires adequate dietary protein — minimum 1.2g per kg of bodyweight, ideally higher. Many GLP-1 users, with appetite suppressed, fall well below this without realising it.
• Genetic facial fat distribution. Some people carry disproportionate facial fat at baseline and lose it faster than average during weight loss. This is not predictable in advance.
• Pre-existing skin laxity. Prior significant weight gain stretches skin and reduces its elasticity. People who have previously gained and lost significant weight are at higher risk.
• High sun exposure history. UV damage degrades collagen over decades. People with significant cumulative sun damage have less collagen reserve when weight loss begins.

Prevention 1: slow the rate of loss

The single most effective intervention is controlling how fast you lose weight. The clinical target for minimising Ozempic face risk while still achieving meaningful results: 0.5–0.75% of bodyweight per week. For a 100kg person, that's 500–750g per week — still substantial over a year, but slow enough for skin to adapt.

On GLP-1 medications, people sometimes lose at 1–1.5% per week without consciously restricting calories — simply because the appetite suppression is so effective that they're eating very little. The prevention strategy here is counterintuitive: eat more deliberately, even when you're not hungry, to keep weekly loss in the protective range.

Practically, this means:

• Weigh yourself weekly and track the trend — not the daily fluctuation
• If you're consistently losing more than 1% per week, increase calorie intake modestly (200–300 kcal/day is often sufficient)
• Consider discussing slower dose escalation with your prescriber if appetite suppression is very aggressive
• Prioritise protein-dense foods that deliver calorie and structural benefit in small volumes

This is exactly the use case for GLP-1 tracking — knowing your weekly loss rate objectively, rather than guessing, allows you to make adjustments before Ozempic face develops rather than after.

Prevention 2: nutrition, hydration, and skincare

Protein. At minimum 1.2g per kg of bodyweight daily — this is the floor for collagen synthesis, not the ceiling. Many sports medicine and bariatric guidelines recommend 1.5–2g/kg during active weight loss to preserve lean mass and support skin integrity. On GLP-1 medications where overall food volume is reduced, prioritising protein at every meal becomes structurally important. Track your intake with tr8ck's nutrition tools to ensure you're hitting the target even when appetite is low.

Hydration. Skin is approximately 64% water. Chronic mild dehydration — common when appetite and thirst signals are both suppressed — reduces skin turgor and accelerates the appearance of laxity. 2–2.5L of water daily is a reasonable baseline; more if you exercise significantly.

Collagen peptides. The evidence base is still developing, but multiple randomised trials have found that hydrolysed collagen supplementation (10–15g/day) modestly improves skin elasticity and hydration over 8–12 weeks. The mechanism is plausible: oral collagen peptides provide the specific amino acid profile (glycine, proline, hydroxyproline) needed for collagen synthesis. Low risk, potentially meaningful benefit during a period of rapid weight loss.

Topical retinoids. Retinoids (tretinoin by prescription, retinol OTC) are the most evidence-backed topical intervention for skin ageing. They accelerate skin cell turnover, stimulate collagen production, and reduce the appearance of fine lines. Starting or maintaining a retinoid routine during GLP-1 treatment is a straightforward preventive step.

SPF daily. UV exposure is the dominant external cause of skin collagen degradation. Daily SPF 30–50 prevents ongoing damage and preserves whatever collagen reserve you have — particularly important during a period when collagen synthesis may already be stressed by rapid weight loss.

FAQ

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making changes to your medication, diet, or exercise routine.